449 related articles for article (PubMed ID: 23939912)
21. THCCOOH concentrations in whole blood: are they useful in discriminating occasional from heavy smokers?
Fabritius M; Favrat B; Chtioui H; Battistella G; Annoni JM; Appenzeller M; Dao K; Fornari E; Lauer E; Mall JF; Maeder P; Mangin P; Staub C; Giroud C
Drug Test Anal; 2014; 6(1-2):155-63. PubMed ID: 24173827
[TBL] [Abstract][Full Text] [Related]
22. Fluorescence-based lateral flow assays for rapid oral fluid roadside detection of cannabis use.
Plouffe BD; Murthy SK
Electrophoresis; 2017 Feb; 38(3-4):501-506. PubMed ID: 27862053
[TBL] [Abstract][Full Text] [Related]
23. Drivers who tested positive for cannabis in oral fluid: a longitudinal analysis of administrative data for Spain between 2011 and 2016.
Herrera-Gómez F; García-Mingo M; Colás M; González-Luque JC; Alvarez FJ
BMJ Open; 2019 Aug; 9(8):e026648. PubMed ID: 31455697
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Cozart DDSV test for cannabis in oral fluid.
Kintz P; Brunet B; Muller JF; Serra W; Villain M; Cirimele V; Mura P
Ther Drug Monit; 2009 Feb; 31(1):131-4. PubMed ID: 19155965
[TBL] [Abstract][Full Text] [Related]
25. Development of a rapid column-switching LC-MS/MS method for the quantification of THCCOOH and THCCOOH-glucuronide in whole blood for assessing cannabis consumption frequency.
Hädener M; Weinmann W; Schürch S; König S
Anal Bioanal Chem; 2016 Mar; 408(7):1953-62. PubMed ID: 26781107
[TBL] [Abstract][Full Text] [Related]
26. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous determination of Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in oral fluid using isotope dilution liquid chromatography tandem mass spectrometry.
Lee PD; Chang YJ; Lin KL; Chang YZ
Anal Bioanal Chem; 2012 Jan; 402(2):851-9. PubMed ID: 22120041
[TBL] [Abstract][Full Text] [Related]
28. Determination of Δ9-tetrahydrocannabinolic acid A (Δ9-THCA-A) in whole blood and plasma by LC-MS/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis.
Raikos N; Schmid H; Nussbaumer S; Ambach L; Lanz S; Längin A; König S; Roth N; Auwärter V; Weinmann W
Forensic Sci Int; 2014 Oct; 243():130-6. PubMed ID: 25173986
[TBL] [Abstract][Full Text] [Related]
29. Cannabis use: a perspective in relation to the proposed UK drug-driving legislation.
Wolff K; Johnston A
Drug Test Anal; 2014; 6(1-2):143-54. PubMed ID: 24327278
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of screening instruments and biomarkers for the detection of cannabis use.
Meersseman P; Vanhoutte S; Van Damme J; Maes L; Lemmens G; Heylens G; Verstraete AG
Subst Abus; 2016; 37(1):176-80. PubMed ID: 26158599
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid.
Kauert GF; Ramaekers JG; Schneider E; Moeller MR; Toennes SW
J Anal Toxicol; 2007 Jun; 31(5):288-93. PubMed ID: 17579974
[TBL] [Abstract][Full Text] [Related]
32. Oral fluid testing for cannabis: on-site OraLine IV s.a.t. device versus GC/MS.
Cirimele V; Villain M; Mura P; Bernard M; Kintz P
Forensic Sci Int; 2006 Sep; 161(2-3):180-4. PubMed ID: 16854544
[TBL] [Abstract][Full Text] [Related]
33. Influence of ethanol on the pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid.
Toennes SW; Schneider K; Wunder C; Kauert GF; Moeller MR; Theunissen EL; Ramaekers JG
J Anal Toxicol; 2013 Apr; 37(3):152-8. PubMed ID: 23429905
[TBL] [Abstract][Full Text] [Related]
34. 11-Nor-9-carboxy-∆9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry.
Scheidweiler KB; Himes SK; Chen X; Liu HF; Huestis MA
Anal Bioanal Chem; 2013 Jul; 405(18):6019-27. PubMed ID: 23681203
[TBL] [Abstract][Full Text] [Related]
35. Development of an electrospray LC-MS/MS method for quantification of Δ(9) -tetrahydrocannabinol and its main metabolite in oral fluid.
Bylda C; Leinenbach A; Thiele R; Kobold U; Volmer DA
Drug Test Anal; 2012; 4(7-8):668-74. PubMed ID: 22374692
[TBL] [Abstract][Full Text] [Related]
36. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
[TBL] [Abstract][Full Text] [Related]
37. THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis".
Pacifici R; Pichini S; Pellegrini M; Rotolo MC; Giorgetti R; Tagliabracci A; Busardò FP; Huestis MA
Clin Chem Lab Med; 2020 Apr; 58(5):682-689. PubMed ID: 30956228
[TBL] [Abstract][Full Text] [Related]
38. The utility of delta 9-tetrahydrocannabinol (THC) measures obtained from oral fluid samples in traffic safety.
Romano E; Moore C; Kelley-Baker T; Torres-Saavedra PA
Traffic Inj Prev; 2019; 20(7):667-672. PubMed ID: 31356118
[No Abstract] [Full Text] [Related]
39. Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users.
Toennes SW; Ramaekers JG; Theunissen EL; Moeller MR; Kauert GF
J Anal Toxicol; 2010 May; 34(4):216-21. PubMed ID: 20465868
[TBL] [Abstract][Full Text] [Related]
40. Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects.
Cone EJ; Bigelow GE; Herrmann ES; Mitchell JM; LoDico C; Flegel R; Vandrey R
J Anal Toxicol; 2015 Sep; 39(7):497-509. PubMed ID: 26139312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
